PRAX:NASDAQ
Praxis Precision Medicines Inc
$310.90
arrow_upward
+1.87%(+5.71) 1D
$320.00
arrow_upward
+2.93% (+9.10)todayPre-market
Closed: Nov 19, 4:00:00 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for PRAX...
Open
$309.24
High
$326.84
Low
$306.68
Mkt. cap
8.69B
Avg. vol.
532.90K
Volume
280.00
52-wk high
$392.70
52-wk low
$160.11
EPS
-$12.79
Beta
2.85
Shares outstanding
27.95M
No. of employees
168
Open
$309.24
High
$326.84
Low
$306.68
Mkt. cap
8.69B
Avg. vol.
532.90K
Volume
280.00
52-wk high
$392.70
52-wk low
$160.11
EPS
-$12.79
Beta
2.85
Shares outstanding
27.95M
No. of employees
168
News stories
From web sources and news partners
Investing.com
·
6 hours ago
B.Riley initiates Praxis Precision Medicines stock with buy rating on drug approvals
About Praxis Precision Medicines Inc
CEO-
Employees168
Founded2015
HeadquartersBoston, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Websitepraxismedicines.com
Analyst ratings
Based on 14 analysts giving stock ratings to PRAX in the past 3 months
Strong buy
Buy
14
Hold
0
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for PRAX in the last 3 months.
Highest
Current $310.90
$1,201.00 (+286.30%)
Average
$736.36 (+136.85%)
Lowest
$478.00 (+53.75%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Tessa Romero J.P. Morgan | Buy | Maintained | $725.00 | +133.2% | 11/20/2026 |
Madison Elsaadi B. Riley Securities | Buy | Initiated | $713.00 | +129.3% | 11/20/2026 |
Kevin Strang Goldman Sachs | Buy | Maintained | $592.00 | +90.4% | 11/17/2026 |
Benjamin Burnett Wells Fargo | Buy | Upgraded | $509.00 | +63.7% | 11/17/2026 |
Brian Skorney Robert W. Baird | Buy | Maintained | $568.00 | +82.7% | 11/16/2026 |
Leonid Timashev RBC Capital | Buy | Maintained | $478.00 | +53.7% | 11/12/2026 |
Yasmeen Rahimi Piper Sandler | Buy | Maintained | $1,200.00 | +286% | 11/13/2026 |
Douglas Tsao H.C. Wainwright | Buy | Maintained | $1,201.00 | +286.3% | 11/13/2026 |
Yatin Suneja Guggenheim | Buy | Reiterated | $1,050.00 | +237.7% | 11/13/2026 |
Justin Walsh JonesTrading | Buy | Reiterated | $534.00 | +71.8% | 11/10/2026 |
Joon Lee UBS | Buy | Maintained | $706.00 | +127.1% | 11/09/2026 |
Jay Olson Oppenheimer | Buy | Reiterated | $650.00 | +109.1% | 11/10/2026 |
Kambiz Yazdi BTIG | Buy | Maintained | $826.00 | +165.7% | 11/09/2026 |
Ami Fadia Needham | Buy | Reiterated | $582.00 | +87.2% | 09/24/2026 |
Tiago Fauth Raymond James | Buy | Maintained | $945.00 | +204% | 08/17/2026 |
Danielle Brill Truist Financial | Buy | Maintained | $616.00 | +98.1% | 08/07/2026 |
Ritu Baral TD Cowen | Buy | Maintained | $510.00 | +64% | 08/06/2026 |
Francois Brisebois LifeSci Capital | Buy | Reiterated | $754.00 | +142.5% | 08/08/2026 |
Andrew Tsai Jefferies | Buy | Maintained | $550.00 | +76.9% | 06/30/2026 |
Laura Chico Wedbush | Sell | Maintained | $162.00 | -47.9% | 06/02/2026 |
David Hoang Deutsche Bank | Buy | Maintained | $374.00 | +20.3% | 06/02/2026 |
Unknown Analyst Raymond James | Buy | Initiated | $815.00 | +162.1% | 04/08/2026 |
Rudy Li Wolfe Research | Buy | Maintained | $500.00 | +60.8% | 04/06/2026 |
Last report
Nov 9, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
-$3.23 / -$3.63
+11.13%beat
arrow_upward
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | - | - | - | - |
Cost of goods sold | 77.51M | 77.99M | 69.42M | 64.20M |
Cost of revenue | 77.51M | 77.99M | 69.42M | 64.20M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 19.54M | 27.87M | 27.49M | 42.71M |
Operating expense | 19.54M | 27.87M | 27.49M | 42.71M |
Total operating expenses | 97.04M | 105.86M | 96.90M | 106.91M |
Operating income | -97.04M | -105.86M | -96.90M | -106.91M |
Other non operating income | - | - | - | - |
EBT including unusual items | -88.91M | -92.56M | -83.72M | -94.23M |
EBT excluding unusual items | -89.58M | -93.22M | -83.72M | -94.23M |
Income tax expense | - | - | - | - |
Effective tax rate | - | - | - | - |
Other operating expenses | - | - | - | - |
Net income | -88.91M | -92.56M | -83.72M | -94.23M |
Net profit margin | - | - | - | - |
Earnings per share | -3.50 | -3.20 | -2.87 | -3.23 |
Interest and investment income | 7.46M | 12.64M | 13.18M | 12.68M |
Interest expense | - | - | - | - |
Net interest expenses | 7.46M | 12.64M | 13.18M | 12.68M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -97.02M | -105.82M | -96.87M | -106.88M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events